CJC-1295 + Ipamorelin + IGF-1 LR3
The third compound removes the one safety feature the first two were chosen for.
The standard growth hormone pair is picked over injected HGH because the body stays in control of how much it releases. IGF-1 LR3 is added to push harder, and it bypasses that control entirely. It is also the second time the stack pays for the same hormone.
The advanced version of the most common stack.
CJC-1295 with ipamorelin is the most searched pairing in the category. This is what people add when it has not done what they hoped.
The reasoning is that the pair works upstream, prompting the body to make more growth hormone, which the liver then converts into IGF-1. IGF-1 is the hormone that does the building. So supplying it directly is presented as cutting out the middleman.
Guides describe this as being for experienced users who have completed at least one cycle of the pair and are willing to commit to bloodwork.[5] That framing is doing a lot of work, and the warnings attached to it are more informative than the pitch.
Four benefits, and how well each one holds up.
The top row is proven and it is a blood marker. The bottom row is the one this page is about.
Three questions, answered before anything else.
Secretagogues are chosen for the brake. This takes the brake off.
The argument for CJC-1295 and ipamorelin over injected growth hormone has always been the same one. They ask the pituitary to release more rather than supplying hormone from outside, so the body's own regulation stays intact.[1]
Somatostatin is the brake. When growth hormone climbs, somatostatin rises and shuts the release down. That is why a secretagogue cannot push the system past a ceiling, and it is presented as the safety advantage of the whole class.
One comparison of the three compounds puts it plainly, describing IGF-1 LR3 as immediate in action but bypassing feedback control, against the pair being gentle, self-limiting and low in overshoot risk.[2]
So the third compound removes the property the first two were selected for. Someone willing to give that up has fewer reasons left to prefer secretagogues over growth hormone itself, which is a question the guides selling this stack do not ask.
The pair already raises IGF-1.
CJC-1295's human trial is the strongest evidence anywhere in this stack. A single dose produced growth hormone elevation of two to ten fold lasting six days or more, with IGF-1 rising one and a half to three fold. Across multiple doses, mean IGF-1 rose 36 to 69 percent depending on dose.[3]
That is the same endpoint the third compound is bought for. The stack is not covering three mechanisms; it is raising one hormone by two routes and then supplying the hormone itself.
The same pattern appears on the tirzepatide and retatrutide page, where two drugs share two of three receptors, and on the NAD+ trio, where all three compounds converge on one molecule.
That trial used CJC-1295 with DAC, the long-acting version. Most blends sold today use the version without it. The pair's own page covers that gap.
Modified so the body cannot clear it.
Natural IGF-1 is controlled after release as well as before it. Binding proteins hold most of it inactive, releasing it gradually, which keeps free levels in a narrow range.
IGF-1 LR3 is engineered to escape those proteins. That is the modification, and it is why the compound is potent. One assessment describes the strength as coming precisely from not being cleared like normal IGF-1, with systemic exposure potentially staying elevated.[2]
The feature and the risk are the same property. There is no version of this compound that is strong without also being hard to switch off.
Two practical consequences follow. IGF-1 has insulin-like activity, so low blood sugar is a recognised concern, and guides recommend limiting use to a few weeks because the receptor downregulates with continuous exposure.[5]
No controlled human study has tested any of this. The published record for IGF-1 LR3 in healthy adults is empty.[4]
IGF-1 and cancer risk.
IGF-1 drives cell growth and division. That is what makes it useful for building tissue, and it is why elevated levels have been studied in cancer research for decades.
A 2020 analysis of the UK Biobank cohort identified associations between elevated circulating IGF-1 and risk across multiple site-specific cancers.[1] That is observational work, meaning it shows an association rather than proving that raising IGF-1 causes cancer.
Every source covering this category lists active or previous cancer as a reason not to use it.[3] Uncontrolled diabetes and significant insulin resistance appear alongside it, since growth hormone opposes insulin.[1]
Guides for this stack describe bloodwork as mandatory rather than advisable, on the grounds that supraphysiological IGF-1 and insulin resistance can develop without symptoms.[5] Anyone running three compounds aimed at one hormone has a clear reason to measure it.
The third compound costs more than the first two together.
IGF-1 LR3 is the expensive part. At the cheapest in-stock listings it costs more than CJC-1295 and ipamorelin combined.[6]
Buying the first two premixed raises the total, since the CJC blend is cheaper per milligram than separate vials but sold in a larger vial. Nobody sells all three together.
Two blends pair IGF-1 LR3 with BPC-157, one of them adding TB-500. Both cost several times any single vial here, and neither states how much of each compound it contains.[6]
Nothing approved, and all three banned.
None of the three has FDA approval. CJC-1295 and ipamorelin both sit in Category 2 on the FDA's 503A bulk substance list as of April 2026, meaning compounding pharmacies may not use them.[1]
WADA bans all three at all times, in and out of competition. Growth hormone releasing factors and IGF-1 analogs are both listed, so a tested athlete taking this stack has committed a doping violation on three counts.
IGF-1 LR3 is sold as a research chemical with no approved label anywhere. Compounded research peptides may carry impurity and sterility risk depending on the supplier.[2]
Sources also warn against use under 25, since growth plates may still be open in some people.[3]
What people ask about this stack
Is adding IGF-1 LR3 worth it?
No human trial has tested it, so the honest answer is that nobody knows. IGF-1 LR3 has no controlled human study for body recomposition, and the combination of all three has never been tested either. What is documented is that the third compound removes the feedback control that makes secretagogues appealing. CJC-1295 also already raises IGF-1 by 36 to 69 percent on its own.
Why does bypassing feedback matter?
Feedback is the reason people choose secretagogues over injected growth hormone. When output rises, somatostatin rises with it and shuts release down, so the system cannot be pushed past a ceiling. IGF-1 LR3 is injected at the end of that chain, so circulating levels no longer depend on it. One comparison describes the pair as gentle, self-limiting and low in overshoot risk, and IGF-1 LR3 as immediate but bypassing feedback control.
What makes IGF-1 LR3 different from IGF-1?
IGF-1 LR3 is modified to escape the binding proteins that normally hold most IGF-1 inactive and release it gradually. That modification is why the compound is potent, and it is also why systemic exposure may stay elevated. The strength and the risk come from the same property, so there is no version that is strong without also being hard to switch off.
What are the risks?
Low blood sugar is recognised, since IGF-1 has insulin-like activity. Receptor downregulation is why guides limit use to a few weeks. The larger question is cancer risk: a 2020 UK Biobank analysis identified associations between elevated circulating IGF-1 and multiple site-specific cancers, which is observational rather than causal. Every source covering this category lists active or previous cancer, and uncontrolled diabetes, as reasons not to use it.
What does it cost?
IGF-1 LR3 is the expensive part, costing more on its own than CJC-1295 and ipamorelin combined. Nobody sells all three premixed. Two blends pair IGF-1 LR3 with BPC-157, one of them adding TB-500, and neither states how much of each compound it contains. Current prices for all three are on the page above.
Can athletes take this stack?
No. All three are banned by WADA at all times, in and out of competition. Growth hormone releasing factors cover CJC-1295, ghrelin receptor agonists cover ipamorelin, and IGF-1 analogs cover IGF-1 LR3, so a tested athlete has committed a violation on three separate counts. Compare against the other stacks.
What this page is built on
- 01Mechanism and risk review of the CJC-1295 and ipamorelin combination. Source for the secretagogue approach preserving regulatory feedback that exogenous growth hormone does not, for both compounds sitting in FDA 503A Category 2 as of April 2026, for no human randomised trial of the combination having been published, and for the Qian and Huo 2020 UK Biobank cohort identifying associations between elevated circulating IGF-1 and risk across multiple site-specific cancers. Also the source for uncontrolled diabetes and significant insulin resistance as contraindications.
- 02Comparison of CJC-1295, ipamorelin and IGF-1 LR3 by pathway. Source for IGF-1 LR3's potency deriving from not being cleared like normal IGF-1 with systemic exposure potentially staying elevated, for the description of it as immediate in action but bypassing feedback control against the pair being gentle, self-limiting and low in overshoot risk, for human muscle evidence being thin for secretagogues and absent for IGF-1 LR3, and for impurity and sterility risk in compounded research peptides.
- 03Teichman SL et al., 2006. Randomised placebo-controlled ascending-dose studies of CJC-1295 in healthy adults. Growth hormone elevated two to ten fold with sustained duration, IGF-1 elevated one and a half to three fold and remaining above baseline for up to 28 days after a single dose, mean IGF-1 increase of 36 to 69 percent across multiple doses. Note: these studies used CJC-1295 with DAC. Also the source for cancer history, pregnancy, uncontrolled diabetes, active pituitary disease and age under 25 as reasons to avoid this class.
- 04Assessment of IGF-1 LR3's evidence base. States that preclinical work suggests anabolic effects but no specific human clinical trials are referenced, that functional medicine descriptions cite no controlled human studies, and that the case rests on mechanistic plausibility and observational use rather than published data.
- 05Protocol guide for the four-compound version of this stack, adding tesamorelin. Source for the stack being framed for experienced users who have completed at least one cycle of CJC-1295 and ipamorelin, for bloodwork being described as mandatory because supraphysiological IGF-1 and insulin resistance can develop silently, for receptor downregulation beyond four to six weeks of continuous IGF-1 LR3 use, and for cumulative hypoglycaemia risk as the reason for limiting duration.
- 06Peptide Decoding vendor pricing data, 26 September 2026. Lowest in-stock single-compound listings for CJC-1295 no DAC, ipamorelin and IGF-1 LR3, computed at page load. No premixed listing of all three. Two blends containing IGF-1 LR3 with BPC-157, one adding TB-500, neither stating composition.